Daaweynta HIV ee Odefsey

Maandooriyaha Isugeynta La Isugu Daray Waxyaabaha Kala Duwan ee La Yidhaahdo

Qeybinta

Odefsey waa hal kiniin ah, daawo isku dhafan oo loo isticmaalo daaweynta HIV, taas oo ka kooban saddex wakiil oo kala duwan:

Odefsey waa daroogada isku dhafan ee labaad si loo isticmaalo TAF, oo ah "kobcin" version of tenofovir disoproxil fumarate (TDF) laga helay daawooyinka Truvada iyo Atripla .

Sidan oo kale, waxaa loo tixgelin karaa horumarinta Complera, oo ah hal-kiniin oo ka kooban rilpivirine + emtricitabine + TDF.

TAF waxaa loo tixgeliyaa inay ka sarreyso TDF maadaama ay awood u leedahay in ay daawada ugu firfircoon u siiso unugyada iyo qiyaaso aad u yar - macnaheedu waxa weeye in ay yaraanta daawada ku jirta dhiigga iyo in yar oo aan la helin horumarinta kaneecada la xiriira daroogada.

(Inkasta oo halista TDF-ku xirxirto sunta sunta ay tahay mid aad u hooseeya dalalka horumaray, khatartaas waxaa loo arkaa in ay si weyn u kicinayso dalalka soo koraya halkaasoo ay jirto xaalad weyn oo ka timaadda cillad kelyo horay u jirtay.

Calaamadaha daaweynta

Odefsey waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka ee Maraykanka 1-dii Maarso, 2016 si loogu isticmaalo labadaba dadka waawayn iyo carruurta da'doodu ka weyn tahay 12 sano oo aan waligood ku jirin daaweynta HIV , kuwaas oo leh fayras fayrus ah 100,000 oo mitir / m ama ka yar, iyo miisaanka 77 rodol (35kg) ama ka badan.

Odefsey ayaa sidoo kale loo isticmaali karaa in lagu badalo daweynta hadda (sida kuwa Complera) haddii bukaanku uu lahaa fayras aan la ogaan karin (<50 unug / mL) ugu yaraan lix bilood, ma laha taariikhda daaweynta oo aan la ogaan, iska caabin kasta oo ka mid ah daroogooyinka qayb ka ah Odefsey.

Dejinta

Odefsey waa kiniin, miisaan, kiniin la duubay, oo ka kooban 25mg oo rilpivirine, 200mg oo emtricitabine iyo 25 mg TAF.

Waxaa ku xeeldheer "GSI" hal dhinac iyo "255" dhinaca kale.

Qiyaasta

Hal kiniin maalinle ah oo la qaato cunto. Odefsey waa in aan lagu qaadin dawooyinka kale ee daawada antiretroviral ee loo isticmaalo daaweynta HIV.

Waxyaabaha kale ee saameynaya

Dhibaatooyin dhinaca daroogada ah ayaa lagu arkay bukaanka bukaan socodka daaweynta qaadashada rilpivirine iyo / ama emtricitabine + TAF, oo ah kuwa ugu badan ee ay ahaayeen:

Dhibaatooyinka kale ayaa caadi ahaan soo noqnoqonaya, iyada oo tiro yar oo bukaanno ah ay joojinayaan sababtoo ah daaweynta xasaasiyadda.

Khilaafaadka

Odefsey waa in aan lagu qaadin daawooyinka soo socda:

Had iyo jeer la socodsii dhakhtarkaaga daroogo kasta ama kudheer, ama laguu qoro, oo laga yaabo inaad qaadato ka hor intaadan bilaabin daaweyn antiretroviral ah.

Tixgelinno Kale

Odefsey laguma talineynin bukaanka qaba naafanimada kelyaha (oo lagu qeexay inay tahay in lagu qiyaaso nadiifinta wax abuurista ee ka yar 30mL daqiiqadii).

Fadlan kugula tali dhakhtarkaaga haddii laguu daaweeyay ama lagu daaweynayo kalyo kasta ee dhakhtarka kale.

Odefsey laguma talineynin bukaanka qaba cilladda beerka ama kuwa qaba infakshanka cagaarshow B (HBV) ee daba dheeraaday sababta oo ah waxay si weyn u sii xumeyn kartaa dhibaatooyinka beerka. Waxaa lagula talinayaa in dadka qaba HIV lagu baaro HBV ka hor inta aysan qorin Odefsey. Fadlan kugula talinay dhakhtarkaaga haddii aad qabtid dhibaato beerka iyo / ama taariikhda cagaarshow.

Qaybta rilpivirine ee Odefsy waxay sababi kartaa dareen-celin aan fiicneyn oo tiro yar oo bukaanno ah, badanaaba qaabka finanka, indhaha indhaha ("pink eye"), bararka wajiga, qandhada, ama xasaasiyad kale.

Caadi ahaan, dareen-celinta dareen-celinta waxay joogtaa 1-6 usbuuc kaddib marka la bilaabayo daweynta. U sheeg dhakhtarkaaga isla markiiba calaamadahaan oo kale. Xaaladaha daran, daaweynta ayaa u badan inay u baahan tahay in la joojiyo.

Ilaha:

Reuters. "BRIEF - Gilead Sciences ayaa sheegaysa in FDA ay ogolaatay Odefsey." La sii daayay March 1, 2015.

Gilead Sciences. " Odefsey - Warbixinaha Wargelinta". Foster City, California; heley March 18, 2016.